SORT1 and cancer: The overexpression of sortilin and its clinicopathological role in cancer has been reported in different types of human solid cancers, including breast (18, 35, 36), neuroendocrine (20), ovarian (25, 37), colorectal (38), and hematological malignancies such as chronic lymphocytic leukemia (CLL) (39) during the last decades.